CoreCap Advisors LLC Lowers Position in Amgen Inc. $AMGN

CoreCap Advisors LLC reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 26.2% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,094 shares of the medical research company’s stock after selling 2,867 shares during the period. CoreCap Advisors LLC’s holdings in Amgen were worth $2,284,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in AMGN. Brighton Jones LLC grew its holdings in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after acquiring an additional 5,226 shares during the period. Caxton Associates LLP acquired a new position in shares of Amgen during the 1st quarter worth $535,000. SCS Capital Management LLC purchased a new position in shares of Amgen in the 1st quarter valued at about $1,687,000. Bayforest Capital Ltd purchased a new position in shares of Amgen in the 1st quarter valued at about $41,000. Finally, Advisory Alpha LLC lifted its stake in shares of Amgen by 12.2% in the first quarter. Advisory Alpha LLC now owns 919 shares of the medical research company’s stock valued at $286,000 after purchasing an additional 100 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Price Performance

Amgen stock opened at $341.64 on Thursday. The stock has a market capitalization of $183.97 billion, a P/E ratio of 26.40, a P/E/G ratio of 3.01 and a beta of 0.45. Amgen Inc. has a 12-month low of $259.82 and a 12-month high of $346.38. The company has a debt-to-equity ratio of 5.45, a current ratio of 1.28 and a quick ratio of 0.99. The firm’s 50-day moving average is $328.43 and its two-hundred day moving average is $303.75.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings data on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. The business had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the previous year, the business posted $5.58 earnings per share. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, February 13th will be given a $2.52 dividend. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. Amgen’s dividend payout ratio (DPR) is presently 73.57%.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on AMGN. Citigroup increased their target price on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. HSBC reaffirmed a “buy” rating and issued a $425.00 price objective on shares of Amgen in a research note on Wednesday, December 10th. Weiss Ratings reiterated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Deutsche Bank Aktiengesellschaft upped their target price on Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a report on Tuesday, November 11th. Finally, Cantor Fitzgerald lifted their price target on Amgen from $305.00 to $315.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $338.50.

Insider Activity at Amgen

In other Amgen news, EVP Murdo Gordon sold 6,879 shares of Amgen stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president directly owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This represents a 11.16% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is currently owned by insiders.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Acquisition strengthens oncology pipeline — Amgen agreed to acquire Dark Blue Therapeutics for up to $840 million, adding a differentiated preclinical AML degrader and expanding its early‑stage oncology discovery capabilities; this is seen as a strategic bolt‑on to Amgen’s cancer portfolio. Amgen Buys Dark Blue In $840 Million Bet On New Leukemia Drugs
• Positive Sentiment: Pipeline progress in obesity — Amgen advanced an early‑stage obesity candidate with a new injection delivery trial, broadening its non‑oncology growth prospects and showing R&D diversification that appeals to long‑term investors. Amgen Advances Early-Stage Obesity Candidate With New Injection Trial
• Neutral Sentiment: Management to present at JPM — Amgen will present at the 44th J.P. Morgan Healthcare Conference; investors will watch for management commentary or guidance updates that could act as a catalyst but this is routine investor outreach. AMGEN TO PRESENT AT THE 44TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
• Neutral Sentiment: Longer‑term product / patent dynamics discussed — Coverage noting how new drug launches and patent risks could reshape Amgen’s growth outlook; useful context for valuation but not an immediate news shock. How New Drug Launches And Patent Risks Are Rewriting The Story For Amgen (AMGN)
• Negative Sentiment: Near‑term earnings pressure expected — previews ahead of Q4 2025 suggest analysts are braced for a low double‑digit profit decline, which could cap near‑term upside and increase sensitivity to upcoming results. What to Expect From Amgen’s Q4 2025 Earnings Report
• Negative Sentiment: License deal implies milestone spend — a report indicates Disco Pharma is set to earn up to $618 million from an Amgen license agreement, signaling a meaningful cash/milestone commitment by Amgen that could weigh on near‑term free cash flow (though it also acquires rights to potentially valuable assets). Disco Pharma set to earn $618M from Amgen license deal

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.